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Abstract Resveratrol (RESV), a polyphenolic natural
compound, has long been acknowledged to have cardio-
protective and antiinflammatory actions. Evidence suggests
that RESV has antioxidant properties that reduce the for-
mation of reactive oxygen species leading to oxidative
stress and apoptotic death of dopaminergic (DAergic)
neurons in Parkinson’s disease (PD). Recent literature has
recognized hyperglycemia as a cause of oxidative stress
reported to be harmful for the nervous system. In this
context, our study aimed (a) to evaluate the effect of RESV
against high glucose (HG)-induced oxidative stress in
DAergic neurons, (b) to study the antiapoptotic properties
of RESV in HG condition, and c) to analyze RESV’s
ability to modulate p53 and GRP75, a p53 inactivator
found to be under expressed in postmortem PD brains. Our
results suggest that RESV protects DAergic neurons
against HG-induced oxidative stress by diminishing cellu-
lar levels of superoxide anion. Moreover, RESV signifi-
cantly reduces HG-induced apoptosis in DAergic cells by
modulating DNA fragmentation and the expression of
several genes implicated in the apoptotic cascade, such as
Bax, Bcl-2, cleaved caspase-3, and cleaved PARP-1. RESV
also prevents the pro-apoptotic increase of p53 in the
nucleus induced by HG. Such data strengthens the corre-
lation between hyperglycemia and neurodegeneration,
while providing new insight on the high occurrence of PD
in patients with diabetes. This study enlightens potent
neuroprotective roles for RESV that should be considered
as a nutritional recommendation for preventive and/or
complementary therapies in controlling neurodegenerative
complications in diabetes.
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Introduction
Glucose is the essential energy substrate of the central
nervous system and large amounts of it are required to fill
the high energetic needs of neurons. Unlike muscle cells or
adipocytes that depend on insulin, glucose uptake in neu-
rons depends mainly on its extracellular concentration
(Tomlinson and Gardiner 2008). Persistent episodes of
long-term glucose exposure may induce oxidative stress
that results in cellular damage (Giaccari et al. 2009), such
as neuropathic complications resulting from hyperglycemia
in uncontrolled diabetes (Rajabally 2011). Accumulating
evidence has enlightened the relationship between diabetes
and neurodegenerative disorders, including Alzheimer’s
disease (AD) (Vignini et al. 2013) and Parkinson’s disease
(PD) (Jagota et al. 2012). Recent literature has reported an
increased risk of developing PD in patients with type 2
diabetes mellitus (Hu et al. 2007; Sun et al. 2012).
PD is a neurodegenerative disorder characterized by the
progressive loss of nigrostriatal dopaminergic (DAergic)
neurons in the substantia nigra pars compacta (SNpc).
DAergic neurons in this region are selectively lost due to
the high activity of monoamine oxidase and elevated levels
of iron which both lead to increased generation of reactive
oxygen species (ROS) (Pearce et al. 1997; Cui et al. 2012).
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At the cellular level, mechanisms of high glucose (HG)-
induced toxicity are similarly sustained by oxidative stress
in vitro (Bournival et al. 2012; Cao et al. 2012) as well as
in vivo (Styskal et al. 2012). By increasing aerobic respi-
ration, raised sugar metabolism promotes excessive for-
mation of ROS which, jointly with insufficient antioxidant
defences, may damage cells (Apel and Hirt 2004). Indeed,
generation of mitochondrial superoxide is increased and is
thought to be at the origin of several HG-induced com-
plications (Brownlee 2001). Currently, it is well known
that oxidative stress may lead to apoptosis (Circu and Aw
2010) and increased production of ROS in HG conditions
may account for glucose neurotoxicity duly observed.
In addition, several genes are known to be implicated in
the pathogenesis of PD, such as PINK1 and DJ-1. Glucose-
regulated protein 75 (GRP75, also called mortalin/
mtHSP70/mot-2), a member of the cytoprotective Hsp70
family of chaperons, interacts with both PINK1 (Jin et al.
2006, 2007; Li et al. 2005; Rakovic et al. 2011) and DJ-1
(Jin et al. 2005; Li et al. 2005). GRP75 is mainly localized
within the mitochondria matrix of neurons where it
accomplishes several functions such as mitochondrial
import and oxidative stress management (Yaguchi et al.
2007). Overexpression of GRP75 leads to extended life
span in nematodes and human cells. On the other hand, it
serves as a major target for oxidation and it was shown to
be involved in aging of nerve cells and in particular in the
degeneration of DAergic neurons (Burbulla et al. 2010). In
mitotic cells, GRP75 localized in the cytoplasm seques-
trates and inactivates p53 preventing its nuclear translo-
cation and apoptosis (Kaul et al. 2001, 2005; Wadhwa et al.
2002). Indeed, p53 is a tumor suppressor protein known to
play an important role in evoking apoptosis when located
in the nucleus by encouraging the transcription of several
pro-apoptotic genes such as Bax (B cell lymphoma 2 [Bcl-
2]-associated X protein, Macip et al. 2003). p53 activity is
stabilized in response to oxidative stress through post-
translational modifications disrupting interactions with
negative regulators (Neilson et al. 2008). It is also a
recurrent target in PD given the involvement of oxidative
stress in p53 activation (Nair 2006) and the evidence of
DNA fragmentation and chromatin condensation in
DAergic neurons of the SNpc in PD patients (Hartmann
and Hirsch 2001; Tatton 2000).
Prevention of neuronal loss in PD has not yet been
addressed by existing symptomatic treatments. Neuropro-
tection by dietary polyphenols may be an interesting avenue
in current attempts to overcome oxidative stress induced by
hyperglycemia. We have recently shown that quercetin and
sesamin, antioxidant polyphenols, exert neuroprotective
effects in neurons exposed to HG (Bournival et al. 2012).
The stilbene resveratrol (RESV) is another polyphenol,
primarily found in red wine, known for its potent
cardioprotective, antiinflammatory, and anticarcinogenic
actions (Rosa et al. 2012; Aluyen et al. 2012). Our group, as
well as others, has highlighted its potential in defending
neurons against oxidative assaults induced by a spectrum of
treatments, including neurotoxins (Ge´linas and Martinoli
2002; Blanchet et al. 2008; Bournival et al. 2009; Peritore
et al. 2012; Wu et al. 2012) or cerebral ischemic injury
(Morris et al. 2011; Sima˜o et al. 2012). Abundant literature
suggests that RESV plays a protective role in several neu-
rodegenerative diseases including PD, AD, and Hunting-
ton’s disease (Albani et al. 2010; Hung et al. 2010) as well
as against neuroinflammation (Foti Cuzzola et al. 2011).
Although the beneficial properties of RESV in neuro-
degenerative diseases are extensively depicted in the lit-
erature, its role in defending neurons against HG-induced
damage has yet to be elucidated. The present study was
designed to examine the neuroprotective effects of the
polyphenol RESV in differentiated DAergic PC12 cells
maintained in HG condition. NGF-differentiated PC12
cells are a reliable model for the investigation of oxidative
stress and neuroprotection of DAergic neurons. They
express tyrosine hydroxylase (TH), high affinity dopamine
transporter, estrogen receptor-a and -b, neurofilaments, and
secrete high levels of dopamine (Kadota et al. 1996;
Neilson et al. 2012; Ge´linas and Martinoli 2002). In this
comprehensive investigation, we outline the roles of RESV
in preventing neural parameters of cellular oxidative stress
and apoptosis induced by HG exposure in a cellular
DAergic system. Our results demonstrate that RESV can
modulate the expression and localization of GPR75, and
thus might mediate mitochondria pathways of cell stress.
Materials and Methods
Drugs and Chemicals
All reagents and chemicals were purchased from Sigma (St.
Louis, MO) unless noted otherwise. Mouse anti-GRP75
(raised against amino acids 525–679 of GRP75 of human
origin), rabbit anti-p53 (raised against full length p53 of
human origin, for immunofluorescence), rabbit anti-Bcl-2
(raised against a peptide mapping at the N-terminus of Bcl-
2 of human origin), rabbit anti-Bax (raised against a peptide
mapping near the N-terminus of Bax of mouse origin),
mouse anticleaved PARP-1 (poly [ADP-ribose] polymer-
ase, raised against C-terminal purified thymus PARP-1 of
calf origin), goat anti-HDAC1 (histone deacetylase 1, raised
against amino acids 450 to C-terminus of human HDAC1),
and mouse anti-GAPDH (glyceraldehyde 3-phosphatase
dehydrogenase, raised against recombinant GAPDH of
human origin) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse anti-p53 (raised
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against amino acids surrounding Ser20 of human p53, for
Western blotting) and rabbit anticleaved caspase-3 (raised
against amino-terminal residues surrounding Asp175 in
human caspase-3) antibodies were purchased from Cell
Signaling (Boston, MA). Rabbit anti-VDAC (voltage-
dependant anion channel, raised against amino acids
152–169 of VDAC of human origin), mouse anti-TH (raised
against rat TH) primary antibodies, and anti-mouse and
-rabbit horseradish peroxidise-conjugated secondary anti-
bodies were purchased from Sigma. Anti-mouse Cy3
(cyanine 3)-conjugated secondary antibody was purchased
from Medicorp (Montreal, QC, Canada). Goat anti-rabbit
FITC (fluorescein isothiocyanate)-conjugated secondary
antibody was purchased from Millipore (Temecula, CA).
Cell Culture and Treatments
PC12 cells, obtained from American Type Culture Col-
lection (ATCC, Rockville, MD), were maintained in a
humidified environment at 37 C and 5 % CO2 atmo-
sphere. Cells were grown in Roswell Park Memorial
Institute medium 1640 (RPMI 1640) supplemented with
10 % (v/v) heat-inactivated horse serum, 5 % (v/v) heat-
inactivated fetal bovine serum (FBS), and gentamicin
(50 lg/mL). PC12 cell neuronal differentiation was evoked
by administration of nerve growth factor-7S (NGF, 50 ng/
mL) in Dulbecco’s Modified Eagle medium (DMEM)
supplemented with 1 % FBS for 7 days, as already
described (Bournival et al. 2009, 2012). The DMEM con-
taining 1.0 g/L of D-glucose (Sigma D5523) is further
called control (CTRL) medium, whereas HG DMEM
containing 4.5 g/L of D-glucose (Sigma D7777) is named
HG medium. DAergic PC12 cells were incubated with
CTRL or HG medium for 96 h, unless stated otherwise. We
previously performed lactate dehydrogenase-based cyto-
toxicity assays to determine the appropriate time of treat-
ment in order to study the apoptotic process in the
remaining live cells (Bournival et al. 2012). For the last
24 h of treatment, DAergic PC12 cells were incubated with
or without RESV (0.1 lM). RESV concentration was
selected after dose response and kinetic studies (Bureau
et al. 2008; Bournival et al. 2009). An osmotic control
consisting of CTRL medium supplemented with 3.5 g/L of
D-mannitol (MANN) was used to rule out a hypertonic
effect of HG medium on PC12 cells. Charcoal-stripped
serum was used in all experiments to ensure that media
were free from steroids. For each experiment, initial
seeding density was 30,000 cells/cm2.
Detection of Mitochondrial Superoxide Radical
DAergic PC12 cells were grown and treated on collagen-
coated circular glass coverslips (Fisher Scientific, Ottawa,
ON, Canada). Intracellular superoxide anion (•O2
-) pro-
duction was measured with MitoSOXTM Red (Invitrogen,
Burlington, ON, Canada), a fluorogenic dye used for the
selective detection of superoxide in the mitochondria of
live cells. After treating cells with CTRL or HG medium
for 3 h with or without RESV, the cells were incubated
with MitoSOXTM Red (5 mM) for 10 min at 37 C. Mit-
oSOXTM Red is rapidly and selectively targeted to the
mitochondria. Once in the mitochondria, it is oxidized by
superoxide and exhibits red fluorescence. Cells were
washed with Hank’s balanced salt solution (HBSS, Invit-
rogen), and Hoechst 33342 counterstained all nuclei. Cells
were fixed in 4 % paraformaldehyde for 6 min at 37 C.
Coverslips were mounted with Molecular Probes’ Pro-
Long Antifade Kit (Invitrogen). Images were acquired by
a Leica SD AF confocal microscope, and analyzed with
Leica Application Suite 3.1.3 software (Leica Microsys-
tems, Concord, ON, Canada). To demonstrate MitoSOXTM
Red selectivity, a positive control was performed using
sodium diethyldithiocarbamate (DDC), a superoxide dis-
mutase (SOD) inhibitor, in CTRL medium.
Immunofluorescence and Terminal Deoxynucleotidyl
Transferase dUTP Nick End Labeling (TUNEL) Assay
Apoptotic cells were also detected by both TUNEL (Roche
Diagnostics, Laval, QC, Canada) assay and activated cas-
pase-3 immunofluorescence. DAergic PC12 cells were
grown and treated on collagen-coated circular glass cov-
erslips. Cells were then fixed in 4 % paraformaldehyde for
15 min at 37 C, washed with phosphate buffered saline
(PBS), and further incubated in a blocking and permeabi-
lizing solution (1 % bovine serum albumin [BSA], 0.18 %
fish skin gelatin, 0.1 % Triton-X, and 0.02 % sodium
azide) for 30 min at RT. Fixed cells were incubated with
polyclonal anticleaved caspase-3 antibody 1:500 in PBS
overnight. The slides were washed and treated with Cy3-
conjugated secondary antibody diluted 1:500 in PBS for
4 h and then incubated with the TUNEL enzyme and
fluorescent dUTP mixture for 1 h at 37 C. Nuclei were
counterstained 40,60-diamidino-2-phenylindole (DAPI).
Coverslips were mounted with ProLong Antifade Kit.
Images were acquired by a Leica SD AF confocal micro-
scope. DAergic PC12 cells were considered to be apoptotic
when they were positive for cleaved caspase-3, and their
nuclei were stained with TUNEL. The number of apoptotic
DAergic PC12 cells among 300 randomly chosen neuronal
was counted on 10 different optical fields from three slides
per group, as already reported (Bournival et al. 2009,
2012), with Leica Application Suite 3.1.3 software. In each
experiment 50 lM Z-DEVD-FMK (Bachem, Torrance,
CA), a cell-permeable caspase-3 inhibitor, was used on
DAergic PC12 cells in HG and HG RESV conditions as
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internal control for caspase-3 activation (Bournival et al.
2009, 2012).
Specific Apoptotic DNA Denaturation Analysis
Specific DNA denaturation in apoptotic cells was assessed
with a single-stranded DNA (ssDNA) apoptosis ELISA kit
(Chemicon International, Temecula, CA). This procedure
is based on the selective denaturation of DNA by form-
amide in apoptotic cells, but not in necrotic cells (Frankfurt
and Krishan 2001). After treatment with CTRL or HG
medium with or without RESV, denatured DNA was
detected with a monoclonal antibody highly specific to
ssDNA and a peroxidase-labeled secondary antibody. The
reaction was then stopped with a hydrochloric acid solu-
tion, and ssDNA fragmentation was quantified by mea-
suring absorbance at 405 nm with a Multiscan Ascent
microplate reader (Thermolab System, Franklin, MA).
ssDNA was quantified with reference to CTRL conditions.
Absorbance of positive (wells coated with ssDNA) and
negative controls (wells treated with S1 nuclease) served as
quality control for the ELISA.
Protein Extraction
DAergic PC12 cells were grown and treated in collagen-
coated 6-well plates. Total proteins were extracted using a
nuclear extraction kit (Active Motif, Carlsbad, CA).
Briefly, cells were washed with a mixture of ice-cold PBS
and phosphatase inhibitors, and then harvested in centri-
fuge tubes. Cell lysis was performed using the supplied
buffer, and samples were centrifuged to obtain membrane-
free supernatants containing total proteins.
Cytoplasmic-nuclear fractionation was achieved using
the nuclear extraction kit. Briefly, cells were washed with a
mixture of ice-cold PBS and phosphatase inhibitors, and
then harvested in centrifuge tubes. Cytoplasmic mem-
branes were ruptured by treatment with a hypotonic buffer
and detergent. Samples were centrifuged to pellet the intact
nuclei, and soluble material was preserved as the cyto-
plasmic fraction. Nuclei were then lysed and conserved in
the provided lysis buffer.
Mitochondrial-cytoplasmic fractionation was achieved
using a mitochondrial extraction kit (Active Motif, Carls-
bad, CA). Cells were washed with a mixture of ice-cold
PBS and phosphatase inhibitors, and then harvested in
centrifuge tubes. Cells were incubated on ice with isotonic
cytosol buffer for 15 min. Cell membranes were ruptured
with a pestle homogenizer. Intact cells and nuclei were
pelleted after two centrifugations and discarded. Superna-
tants containing cytoplasm and mitochondria were centri-
fuged twice to obtain a pellet of mitochondria. The
resulting supernatant was preserved as the cytoplasmic
fraction. Mitochondria were washed with cytosol buffer
and lysed with detergent.
Electrophoresis and Western Blotting Analysis
Protein dosage was performed with a bicinchoninic acid-
based sodium dodecyl sulfate (SDS)-compatible Protein
Assay Kit (Pierce, Rockfort, IL) for each fraction of every
sample. Equal amounts of protein were loaded onto 12 %
SDS polyacrylamide gels. After electrophoretic separation,
the gels were transferred to polyvinylidene difluoride
membranes (0.22 lm pore size, BioRad, Hercules, CA).
The blots were blocked for 1 h at room temperature (RT) in
Blotto B (1 % nonfat powdered milk, 1 % BSA, 0.05 %
Tween 20, 0.5 mg/mL sodium azide, in Tris buffered sal-
ine). Dilution of primary anti-GRP75, anti-p53, anti-Bax,
anti-Bcl-2, anti-cleaved PARP-1, anti-GAPDH, anti-
HDAC1, anti-VDAC, and anti-TH (1:200, 1:200, 1:50,
1:50, 1:1,000, 1:50, 1:50, 1:500, and 1:10,000, respec-
tively) antibodies was prepared in Blotto B. The blots were
then incubated with peroxidase-conjugated secondary
antibody (1:10,000) in Blotto B for 2 h at RT and finally
developed with an enhanced chemiluminescence substrate
solution (Haan and Behrmann 2007).
GRP75-p53 Colocalization
DAergic PC12 cells were grown and treated on collagen-
coated circular glass coverslips. Then, they were fixed in
4 % paraformaldehyde for 15 min at 37 C, washed with
PBS, and further incubated in a blocking and permeabi-
lizing solution for 30 min at RT. Fixed cells were incu-
bated with both rabbit anti-p53 antibody 1:100 and
mouse anti-GRP75 1:100 in PBS overnight. The slides
were washed with and subsequently treated with anti-
rabbit Cy3-conjugated and anti-rabbit FITC-conjugated
secondary antibodies both diluted 1:500 in PBS for 4 h.
Nuclei were counterstained with DAPI. Coverslips were
mounted with Molecular Probes’ ProLong Antifade Kit.
Images were acquired by a Leica SD AF confocal
microscope. Colocalization was assessed for 100 ran-
domly chosen DAergic PC12 cells on 6 different optical
fields from three slides per group with Leica Application
Suite 3.1.3 software.
Statistical Analysis
Significant differences between groups were ascertained by
one-way analysis of variance (ANOVA), followed by Tu-
key’s post hoc analysis with the GraphPad Instat program,
version 3.06 for Windows (San Diego, CA; www.
graphpad.com). All data, analyzed at the 95 % confi-
dence interval, are expressed as mean ± standard error of
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the mean (SEM) from at least 3 independent experiments.
Asterisks indicate statistical differences between the
treatment and CTRL condition (***p \ 0.001, **p \ 0.01,
and *p \ 0.05); plus signs show statistical differences
between the treatment and HG condition (???p \ 0.001,
??p \ 0.01, and ?p \ 0.05).
Results
RESV Rescues HG Production of Superoxide
To study the mechanisms underlying the neuroprotective
effects of RESV against HG, we measured the production
of superoxide with a derivative of ethidium bromide,
MitoSOXTM Red, after administration of HG with or
without RESV for 3 h. This time period was considered,
since free radical generation and eventually oxidative stress
are early events in the causative process of cellular death
(Zhou et al. 2008; Pe´rez-De La Cruz et al. 2010, Carange
et al. 2011). Figure 1a discloses low fluorescence levels in
CTRL and MANN conditions as well as in cells treated
with RESV in CTRL medium after 24 h, whereas a marked
signal was detected in HG- and DDC-treated cells. When
RESV was added to HG medium, fluorescence was
strongly reduced. Figure 1b also reports the semiquantita-
tive analysis of mitochondrial superoxide anion presented
in Fig. 1a, revealing high fluorescence levels with HG and
positive control DDC as well as a very significant reduction
(p [ 0.001) when DAergic PC12 cells in HG medium were
treated with RESV. In the DDC condition, inhibition of
SOD supports the specific detection of superoxide anion.
All nuclei are stained blue by Hoechst 33342 (Fig. 1a).
RESV Reduces HG-Induced Apoptosis
We measured DNA denaturation induced by formamide, a
specific hallmark of apoptosis (Frankfurt and Krishan
2001), using a ssDNA specific antibody (Fig. 2a). Specific
apoptotic DNA denaturation is observed in early as well as
in late apoptotic cells. HG condition showed a 43 %
increase in apoptotic cells in comparison to CTRL wells.
This increment was fully reversed by RESV treatment in
HG medium (Fig. 2a). MANN medium did not yield sig-
nificant apoptosis.
We then examined the effect of HG and RESV on
later events of the apoptotic cascade leading to DNA
fragmentation. Detection of cleaved caspase-3, the ter-
minal effector caspase responsible for late apoptosis-
mediated DNA fragmentation (Fan et al. 2005), was
conducted by immunofluorescence alongside a TUNEL
Fig. 1 RESV reduces HG-induced superoxide anion production in
DAergic PC12 cells. a Fluorescence microphotographs. Blue: DAer-
gic PC12 nuclei counterstained with Hoechst 33342. Red: MitoS-
OXTM Red superoxide indicator signal. A marked red signal is
evident in DAergic PC12 cells treated with HG or DDC (CTRL
medium ? DDC). Red fluorescence was less intense in cells treated
with CTRL medium, RESV alone or when RESV was added in HG
medium (HG RESV). b Semiquantitative image analysis. Fluorescent
units (F.U.). ***p \ 0.001 compared with CTRL, ???p \ 0.001
compared with HG, as determined by one-way ANOVA, followed by
Tukey’s multiple-comparison test (Color figure online)
b
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assay measuring DNA degradation (Fig. 2b, c). In the
HG condition, immunofluorescence revealed the presence
of cleaved caspase-3 positive cells (Fig. 2c, red signal),
while TUNEL assay stained numerous nuclei undergoing
DNA fragmentation (Fig. 2c, green signal). Total nuclei
were stained with DAPI (Fig. 2c, blue signal). DAergic
PC12 cells were considered to be in late apoptosis when
they hosted both caspase-3 activation and DNA frag-
mentation events (Fig. 2c, cells pointed by white
arrows). Treatment with RESV for 24 h clearly reduced
the presence of apoptotic nuclei as implied by the lower
number of DAergic PC12 cells exhibiting both green and
red fluorescence. The number of apoptotic cells was also
counted (Fig. 2b), as described in the Materials and
Methods section. Administration of RESV decreased the
number of apoptotic cells compared to the HG condition.
MANN medium did not yield a significant rise in
apoptotic cells compared to CTRL. To show that cas-
pase-3 activation is a key step in the HG-induced
apoptotic pathway, DAergic PC12 cells were pretreated
with 50 lM Z-DEVD-FMK, a cell-permeable selective
caspase-3 inhibitor, followed by treatment with HG with
or without RESV (Fig. 2b, c).
In order to further support these findings, we analyzed
the expression of several proteins acting in the apoptotic
cascade. Western blotting was performed on total pro-
teins extracted from DAergic PC12 cells treated with HG
or CTRL medium, with or without RESV (Fig. 3). We
analyzed the pro-apoptotic Bax and antiapoptotic Bcl-2
protein ratio (Fig. 3a) reported to be correlated with
apoptosis (Cory and Adams 2002). A high Bax/Bcl-2
ratio favors the release of mitochondrial factors leading
to the activation of effector caspases in the apoptotic
cascade (Kang and Reynolds 2009). Our results demon-
strate that the administration of HG medium for 96 h
increases the Bax/Bcl-2 ratio two-fold compared to
CTRL medium, supporting that HG-induced apoptosis in
DAergic PC12 cells is mediated, at least in part, by the
mitochondrial pathway (Fig. 3a, histogram full gray line).
The HG-induced raise of the Bax/Bcl-2 ratio was fully
reversed in DAergic PC12 cells treated with RESV.
Explicitly, HG medium increases Bax expression
(Fig. 3a, histogram white bars, Bax Western bands), but
does not modulate Bcl-2 (Fig. 3a, histogram black bars,
Bcl-2 Western bands). RESV reverses the HG-induced
increase in Bax expression and increases Bcl-2 expres-
sion. We also examined the ratio of full-length PARP-1
on inactivated cleaved PARP-1 (Fig. 3b). As Chaitanya
et al. (2010) have demonstrated, PARP-1 is a major
Fig. 2 RESV reduces HG-induced apoptosis in DAergic PC12 cells
a Histogram of specific apoptotic DNA denaturation by formamide in
DAergic PC12 cells as detected with a monoclonal antibody against
ssDNA. CTRL, MANN, and RESV alone do not affect specific
apoptotic DNA denaturation. HG increases apoptotic DNA denatur-
ation. Treatment of HG-exposed cells with RESV elicits a significant
decrease in specific apoptotic DNA denaturation (HG RESV). b The
number of apoptotic DAergic cells among 300 randomly chosen
DAergic cells was counted on 10 different optical fields from 3 slides
per group, as illustrated in Fig. 2c. c Microphotographs of immuno-
fluorescence detection of apoptotic DAergic PC12 cells. Blue:
DAergic PC12 nuclei counterstained with DAPI. Red: anticleaved
caspase-3 signal. Green: TUNEL staining of nuclei exhibiting DNA
fragmentation. Triple-staining (cells points by white arrows) clearly
reveals several apoptotic cells on slides treated with HG and fewer
apoptotic cells when DAergic PC12 cells are treated with CTRL
medium, RESV alone or when RESV is administered in HG
conditions (HG RESV). To show that caspase-3 activation is a key
step in the HG-induced apoptotic pathway, DAergic PC12 cells were
pretreated with 50 lM Z-DEVD-FMK, a cell-permeable caspase-3
inhibitor, followed by treatment with HG, with or without RESV (HG-
Z-DEVD-FMK and HG RESV-Z-DEVD-FMK, respectively). MANN
condition is similar to CTRL cells. Enlarged microphotograph: HG
merge, to show apoptotic nuclei in HG condition. **p \ 0.01 and
***p \ 0.001 compared with CTRL, ?p\0.05, ??p \ 0.01, and
???p \ 0.001 compared with HG, as determined by one-way
ANOVA, followed by Tukey’s multiple-comparison test (Color figure
online)
b
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Fig. 2 continued
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player in the prevention of programmed cell death and
its cleavage by activated caspase-3 is a hallmark of
apoptosis. HG treatment markedly reduced full-length/
cleaved ratio, which was fully reversed by RESV
administered in HG medium (Fig. 3b, histogram full gray
line). MANN medium did not have a substantial effect
on either the Bax/Bcl-2 ratio or the PARP-1 full-length/
cleaved ratio. HG increased PARP-1 cleavage, while
RESV prevented this rise (Fig. 3b, histogram black bars,
cleaved PARP-1 Western bands). Full-length PARP-
1expression was not affected in any condition (Fig. 3b,
histogram white bars, full-length PARP-1 Western
bands).
RESV Modulates p53 and GRP75 Subcellular
Localization and Colocalization
We studied the expression levels of p53, a tumor sup-
pressor, and GRP75, a stress response protein (Fig. 4). In
several models, GRP75 binds and inactivates pro-apoptotic
Fig. 3 RESV modulates the expression of apoptotic protein markers.
a Effect of RESV on the Bax/Bcl-2 ratio in DAergic PC12 cells (full
gray line). CTRL, MANN, and RESV alone do not modulate the Bax/
Bcl-2 ratio. HG increases the Bax/Bcl-2 ratio significantly and the
addition of RESV to HG medium strongly prevents this increment
(HG RESV). Bottom: Bax and Bcl-2 bands, as revealed by Western
blotting. b Analysis of PARP-1 protein expression. These results are
presented as the ratio of full-length (white bars)/cleaved (black bars)
PARP-1. CTRL, MANN, and RESV alone do not modulate the
PARP-1 ratio in DAergic PC12 cells (full gray line). A decrease of
PARP-1 ratio is apparent in HG condition. When RESV is delivered
in HG condition, a significant increase of full-length/cleaved PARP-1
was evident (HG RESV). Bottom: Western blot bands of full-length
and cleaved PARP-1. **p \ 0.01, ***p \ 0.001 compared with
CTRL and ?p\0.05, ???p \ 0.001 compared with HG, as deter-
mined by one-way ANOVA, followed by Tukey’s multiple-compar-
ison test
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p53 in the cytosol, therefore helping to prevent apoptosis.
In order to elucidate this alleged relationship between both
markers, protein levels were measured in the cytoplasm
and the nucleus (p53) or in the cytoplasm and the mito-
chondria (GRP75) (Fig. 4a and b). Treatment of DAergic
PC12 cells with HG medium for 96 h noticeably decreased
p53 cytoplasmic/nuclear ratio (Fig. 4a, histogram full gray
line). This was prevented by administration with RESV.
Expressly, HG increased p53 expression in the nucleus
(Fig. 4a, histogram black bars, p53 nuclear Western
bands), while it did not seem to affect cytoplasmic levels
(Fig. 4a, histogram white bars, p53 cytoplasmic Western
bands). RESV in HG medium preserved p53 levels at
CTRL range in both compartments. HG administration for
96 h increased GRP75 expression both in the cytoplasm
and in the mitochondria (Fig. 4b, histogram white and
black bars, GRP75 mitochondrial, and cytoplasmic Wes-
tern bands). Treatment with RESV in HG medium pre-
vented GRP75 levels from rising in the cytoplasmic
fraction only. The result is a small, but significant decrease
in the GRP75 cytoplasmic/mitochondrial ratio (Fig. 4b,
histogram full gray line). MANN medium did not affect the
expression of either GRP75 or p53.
Finally, to evaluate the potential for GRP75 and p53 to
interact in the cytoplasm, immunofluorescence colocaliza-
tion measurements were performed following treatment of
DAergic PC12 cells with HG medium with or without
RESV. Scatter plots show that p53 (Fig. 5a, green signal
distribution) and GRP75 (Fig. 5a, red signal distribution)
signals are mainly independent from one another except for
slight colocalization (Fig. 5a, plots and micrographs,
Fig. 5b). However, treatment with HG medium still
appears to yield more colocalization on the scatter plot
(Fig. 5a, plots), which is also supported by the
colocalization rate histogram (Fig. 5b). Overlaid pictures
of p53 and GRP75 staining (Fig. 5a, micrographs) in
CTRL, MANN, and RESV condition show dispersed
punctual staining (white signal) in the cytoplasm, while in
the HG condition a perinuclear dense staining is clearly
visible. Administration of RESV in HG medium reveals a
more scattered staining than in HG condition alone.
Discussion
We previously reported that several natural polyphenols,
including the stilbene RESV, exert powerful neuroprotec-
tive activity in DAergic PC12 cells against the oxidative
burden triggered by the administration of the potent par-
kinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP) in vivo (Blanchet et al. 2008) or its active
metabolite 1-methyl-4-phenylpyridinium (MPP?) in vitro
(Gagne´ et al. 2003; Lahaie-Collins et al. 2008; Bournival
et al. 2009). Since hyperglycemia has also been listed as a
growing risk factor for PD (Hu et al. 2007; Jagota et al.
2012; Sun et al. 2012), we focused our study on the neu-
roprotective effect of RESV on HG-induced oxidative
stress and apoptosis in DAergic PC12 cells with regard to
GRP75 and p53 localization.
The Diabetes Control and Complications Trial (1993)
together with the U.K. Prospective Diabetes Study (1998)
have determined that hyperglycemia is the culprit to blame
for tissue damage in type I and type II diabetes. Currently,
we know that overproduction of superoxide is the single
upstream event leading to the following pathways involved
in glucose toxicity (Giacco and Brownlee 2010): (1)
increased flux of glucose and other sugars through the
polyol pathway; (2) increased intracellular formation of
advanced glycation end products (AGEs); (3) increased
expression of the receptor for AGEs and its activating
ligands; (4) activation of protein kinase C (PKC) isoforms;
and (5) overeactivity of the hexosamine pathway. The
formation of AGEs and activation of AGE receptors
(Shaikh and Nicholson 2008), the activation of PKC (Aoki
and Li 2011), and the dysfunction of the polyol pathway
(Ahmed et al. 2009) have been identified as contributors in
the development of PD. These mechanisms suggest a
strong link between neuronal apoptosis observed in PD and
hyperglycemic damage in diabetes (Li et al. 2002, 2008;
Klein et al. 2004).
In this study, we demonstrated the defensive role of
RESV in counteracting cellular distress parameters evoked
by HG in DAergic PC12 cells. We tested NGF-differenti-
ated PC12 cells, a known, reliable, and efficient model for
the investigation of oxidative stress, apoptosis, and neu-
roprotection of DAergic neurons (Ge´linas and Martinoli
2002; Lahaie-Collins et al. 2008; Bournival et al. 2012).
Fig. 4 a Effect of RESV on the cellular localization of p53 in
DAergic PC12 cells. HG medium significantly increases nuclear
localization of p53 (black bars) and administration of RESV in HG
medium prevents this increase (HG RESV). RESV and MANN alone
do not modulate p53 cellular localization. Cytoplasmic p53 (white
bars) is not affected in any condition. Ratio of cytoplasmic/nuclear
p53 is decreased in HG condition, which is prevented by RESV
administration (HG RESV, full gray line). Bottom: p53, cytoplasmic
fraction purity marker TH and nuclear fraction purity marker HDAC1
bands as revealed by Western blotting. b Effect of RESV on the
cellular localization of GRP75 in DAergic PC12 cells. HG treatment
increases both cytoplasmic and mitochondrial content of GRP75.
Administration of RESV in HG medium (HG RESV) significantly
reduces cytoplasmic levels of GRP75 (white bars), while it does not
amend mitochondrial levels (black bars). Ratio of cytoplasmic/
mitochondria GRP75 is decreased in HG condition, which is
prevented by RESV administration (HG RESV, full gray line).
Bottom: GRP75, cytoplasmic fraction purity marker GAPDH and
mitochondrial fraction purity marker VDAC bands, as revealed by
Western blotting. **p \ 0.01, ***p \ 0.001 compared with CTRL
and ?p\0.05, ??p \ 0.01 compared with HG, as determined by one-
way ANOVA, followed by Tukey’s multiple-comparison test
b
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Since oxidative stress is an essential factor in glucose
toxicity and in the pathogenesis of PD, we investigated
whether RESV protects DAergic PC12 cells by reducing
levels of mitochondrial superoxide in HG condition. Our
results show that RESV effectively diminishes superoxide
production after as early as 3 h suggesting that oxidative
damages occurs upstream of apoptosis. In PD, superoxide
reacts with iron cations to form hydroxyl radical
(Ramasarma 2012), known to exert very deleterious effects
on DNA, lipids, and proteins. This ROS can also react with
nitric oxide, an important signaling molecule in the brain,
to form peroxynitrite, a powerful oxidant shown to play a
significant role in protein aggregation pertinent to PD
(Danielson and Andersen 2008).
It is currently well known that oxidative stress may
cause apoptosis through several pathways: (1) ROS-
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induced expression or activation of nuclear factor-kappa B
(NF-jB) (Gloire et al. 2006); (2) mitochondria-mediated
cell apoptosis (Circu and Aw 2010); (3) ROS-mediated
DNA damage and p53 activation (Liu and Xu 2011); and
(4) stress-activated protein kinases pathway to apoptosis
(Johnson and Nakamura 2007). We performed a set of
experiments to investigate the apoptotic cascade in DAer-
gic PC12 cells ensuing oxidative stress to further demon-
strate the preventive role of RESV. A specific apoptotic
DNA denaturation assay demonstrated that RESV signifi-
cantly prevents apoptosis in cells exposed to HG. We
further examined markers of late apoptosis to determine
whether the protein cascade leads to terminal events such
as the irreversible fragmentation of DNA. RESV in HG
clearly reduced the number of apoptotic PC12 cells in
comparison to the HG condition alone as shown by the
decline in TUNEL and cleaved caspase-3 double-positive
cells. Another target of activated caspase-3 is PARP-1, a
protein known to participate in the repair of damaged DNA
(Wang et al. 2012). Our findings reveal that the PARP-1
protein ratio, full-length versus cleaved, was decreased
after HG treatment and was then improved by RESV
administration, hence supporting once more the neuropro-
tective antiapoptotic role of RESV in a HG paradigm. In
addition, the Bax and Bcl-2 expression were studied to
determine the apoptotic events surrounding the mitochon-
dria. Bax contributes to the leakiness of the outer mito-
chondrial membrane, while Bcl-2 blocks the permeability
transition pore, thus inhibiting mitochondria-mediated
programmed cell death (Smith et al. 2008). The rise in the
Bax to Bcl-2 ratio is a characteristic feature in apoptosis
(Cory and Adams 2002) equally observed in glucose
toxicity (Allen et al. 2005) and in several models of PD
including human postmortem brains (Vila and Perier
2008). Our data reveal that the Bax/Bcl-2 protein ratio is
increased after HG administration, and is decreased by
RESV treatment in the HG condition, strongly suggestive
of a role for mitochondrial dysfunction in the mechanisms
underlying the apoptosis of DAergic neurons in our cellular
paradigm of hyperglycemia.
GRP75 has often been linked to PD pathogenesis as
reported in studies showing binding properties to PD-
associated proteins in the mitochondria (Li et al. 2005; Jin
et al. 2005, 2006, 2007; Rakovic et al. 2011) and reduced
levels of the protein in postmortem PD brain samples (Jin
et al. 2005; Shi et al. 2008; Burbulla et al. 2010). While
GRP75 is mainly confined to the outer membrane of
mitochondria, several studies have shown that it may bind
and sequestrate pro-apoptotic p53 in the cytosol thereby
preventing its entry in the nucleus, impeding apoptosis and
ultimately promoting p53 degradation by the MDM2 pro-
teasome degradation pathway (Kaul et al. 2001; Wadhwa
et al. 2002; Kaul et al. 2005). Such studies were mainly
conducted in cancer cells (Kaul et al. 2001, 2005; Wadhwa
et al. 2002) or in naive, mitotic PC12 cells (Guo et al. 2009;
Li et al. 2011). Our results obtained in post-mitotic PC12
cells, show that HG treatment increases GRP75 expression
in the cytoplasm as well as in mitochondria thus suggesting
that GRP75 is induced by HG cellular stress. While RESV
reduced GRP75 levels in the cytoplasm, it did not ensure a
significant effect in diminishing mitochondria GRP75
localization. Apparently, in our cellular paradigm, RESV
modulates the subcellular distribution of GRP75 by pre-
venting cytoplasmic levels from rising. RESV may be
responsible for quenching HG-induced stress signals that
promote the induction of GRP75 in the cytoplasm. More-
over, p53 localization is increased in the nucleus, which
points toward a pro-apoptotic effect of HG on DAergic
PC12 cells. RESV in HG medium maintains the cellular
distribution of p53, which partially accounts for its anti-
apoptotic properties. Altogether, these results show an
increase of GRP75 in the cytoplasm, while p53 levels rise
significantly in the nucleus in HG condition, suggesting
relatively weak interaction between both markers in post-
mitotic cells. Colocalization studies deepened our under-
standing of the relationship between GRP75 and p53 in our
cellular model. We show that GRP75 and p53 have a
potential to bind in the cytoplasm, but to a limited extent.
Binding in HG condition is significantly enhanced, perhaps
due to increased expression of both proteins in the cyto-
plasm, but still remains limited. We show for the first time
that post-mitotic DAergic PC12 cells exert weak binding of
GRP75 and p53, which contrasts with findings in nondif-
ferentiated mitotic PC12 cells (Guo et al. 2009; Li et al.
2011). Altogether, our results demonstrate that HG-induced
Fig. 5 RESV modulates p53 and GRP75 colocalization. a Scatter
plots and corresponding overlaid micrographs of p53 and GRP75.
Scatter plots show signal intensity for p53 (green signal) on the y-axis
and GRP75 (red signal) on the x-axis. Each dot represents one event
of fluorescent signal. Thresholds for green and red signal are
optimized at 85 % (two white lines) and mean background at 10 %
(arched delimitation), in each condition. Signal is colocalized when
signals in scatter plots are located between the threshold lines on the
outside of the background delimitation. White signal in microphoto-
graphs indicates high probability of colocalization. CTRL, RESV, and
MANN conditions are similar in that p53 and GRP75 colocalization is
scarce and scattered in the cell cytoplasm. HG increases the white
signal around the perinuclear area as well as the number of dots in the
region of interest on the plot. Treatment with RESV yields a scatter
plot and overlaid white signal (HG RESV) similar to the CTRL
condition, suggesting its potential to diminish colocalization between
GRP75 and p53. b Histogram depicting the colocalization rate of
GRP75 and p53 observed in Fig. 5a. HG increases the colocalization
rate significantly. RESV administration in HG medium reverses this
increase in colocalization rate (HG RESV). All other conditions are
similar to CTRL. ***p \ 0.001 compared with CTRL and
??p \ 0.001 compared with HG, as determined by one-way
ANOVA, followed by Tukey’s multiple-comparison test (Color
figure online)
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oxidative stress and apoptosis of DAergic PC12 cells can
be improved by RESV, sustaining an important role for this
naturally occurring polyphenol in diabetes treatment.
RESV has been the object of several diabetes studies
because of its ability to improve insulin sensitivity, protect
pancreatic b cells, and control glycaemia (Milne et al.
2007; Szkudelski and Szkudelska 2011; Lee et al. 2012).
Indeed, RESV protects against retinopathy in rats with
diabetes (Soufi et al. 2012) and prevents nephropathy in db/
db mice by inhibiting lipotoxicity-related apoptosis and
oxidative stress in the kidney (Kim et al. 2013). Additional
beneficial effects of the stilbene RESV may contribute to
alleviate obesity-induced metabolic complications (Rose-
now et al. 2012) often related with diabetes. A recent
clinical study has found oral administration of RESV to be
effective in improving glycaemia in type 2 diabetes mel-
litus (Bhatt et al. 2012).
Even though RESV is principally metabolized into its
glucoronide and sulfate conjugates, recent data show that
these metabolites may possess beneficial properties
(Delmas et al. 2011). Increased bioavailability due to a
synergistic effect with other polyphenols or compounds,
such as curcumin or the glycemic control drug metfor-
min, must also be taken into account (Bruckbauer and
Zemel 2013; Du et al. 2013). Besides, recent pharma-
cological advances have improved bioavailability of
RESV (for details see Amiot et al. 2013; Neves et al.
2013). Finally, the potential beneficial properties of
RESV on human health are broadly displayed in the
literature and justify the need to further unravel the
powerful cellular role of this dietary polyphenol.
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